EMEA-001329-PIP02-13
Key facts
| Active substance |
Expanded autologous bone marrow-derived osteoblastic cells
|
| Therapeutic area |
Other
|
| Decision number |
P/0164/2014
|
| PIP number |
EMEA-001329-PIP02-13
|
| Pharmaceutical form(s) |
Suspension for injection
|
| Condition(s) / indication(s) |
Treatment of non-traumatic osteonecrosis
|
| Route(s) of administration |
Intraosseous use
|
| Contact for public enquiries |
Bone Therapeutics S.A.
|
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|
Decision
-
List item
Public summary of the evaluation of the proposed paediatric investigation plan: human autologous bone marrow-derived osteoblastic cells for the treatment of non-traumatic osteonecrosis (PDF/84.48 KB)
First published: 31/07/2014
Last updated: 31/07/2014
EMA/426630/2014 -
List item
Human autologous bone marrow-derived osteoblastic cells: Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision (PDF/100.33 KB)
First published: 26/02/2019